OPEN

A suicide inhibitor of nematode trehalose-6-phosphate phosphatases

Megan Cross¹, Mark York², Ewa Długosz³, Jan Hendrik Straub¹, Sonja Biberacher¹, H. M. P. Dilrukshi Herath⁴, Stephanie A. Logan², Jeong-Sun Kim⁵, Robin B. Gasser⁴, John H. Ryan² & Andreas Hofmann^{1,4,6*}

Protein-based drug discovery strategies have the distinct advantage of providing insights into the molecular mechanisms of chemical effectors. Currently, there are no known trehalose-6-phosphate phosphatase (TPP) inhibitors that possess reasonable inhibition constants and chemical scaffolds amenable to convenient modification. In the present study, we subjected recombinant TPPs to a two-tiered screening approach to evaluate several diverse compound groups with respect to their potential as TPP inhibitors. From a total of 5452 compounds tested, *N*-(phenylthio)phthalimide was identified as an inhibitor of nematode TPPs with apparent K_i values of 1.0 μM and 0.56 μM against the enzymes from the zoonotic roundworms *Ancylostoma ceylanicum* and *Toxocara canis*, respectively. Using site-directed mutagenesis, we demonstrate that this compound acts as a suicide inhibitor that conjugates a strictly conserved cysteine residue in the vicinity of the active site of nematode TPPs. The anthelmintic properties of *N*-(phenylthio)phthalimide were assessed in whole nematode assays using larvae of the ascarids *T. canis* and *T. cati*, as well as the barber's pole worm *Haemonchus contortus*. The compound was particularly effective against each of the ascarids with an IC_{50} value of 9.3 μM in the survival assay of *T. cati* larvae, whereas no bioactivity was observed against *H. contortus*.

Although in the public perception risks from infectious diseases caused by parasitic worms (helminths) of humans, animals and plants are often ranked moderate or low¹, many of these diseases have a substantial impact in agriculture, the environment and human health. In particular, with currently >1 billion people infected by roundworms (nematodes)² the resultant morbidity surpasses diabetes and lung cancer in disability-adjusted life years³. Worm infections of live stock currently cause annual economic losses of 500 million dollars in Australia alone⁴. In the absence of vaccines for the majority of these parasites, their control relies predominantly on the use of anthelmintics, whose wide-spread use has led to drug resistance problems^{5,6}. The present anthropogenic trends as well as the globally changing climate has further resulted in the establishment of parasitic organisms in new habitats⁷. Additionally, an increasing importance of zoonosis⁸ is expected, exemplified by the emerging prevalence of roundworms including *Ancylostoma ceylanicum*^{9,10} and *Toxocara canis*^{11,12} and their effects in humans^{12–14}. Toxocariasis, caused by *T. canis* (dog roundworm) and *T. cati* (cat roundworm), is classified as a neglected parasitic infection that is targeted by the US Centers for Disease Control and Prevention (CDC) for urgent public health action, owing to the threat posed by zoonosis¹⁵. Other nematode infections, such as haemonchiasis, cause substantial economic losses. The livestock nematode *Haemonchus contortus* (barber's pole worm) colonises the abomasum in cattle, goats and other wild ruminants and can induce anemia and edema as well as other intestinal disturbances¹⁶. Often, the host will die with major infections. Therefore, the discovery and development of novel therapeutics is an urgent aim to ensure appropriate control measures for helminths in the future.

The increasing availability of genomic, transcriptomic and proteomic datasets of pathogenic organisms opens up avenues for advanced molecular approaches for drug discovery that utilise data mining to identify novel targets^{17,18}. One such target identified by combining genome data set mining and literature research is the enzyme

¹Griffith Institute for Drug Discovery, Griffith University, Nathan, Queensland, 4111, Australia. ²CSIRO Biomedical Manufacturing Program, Clayton, Victoria, 3168, Australia. ³Department of Preclinical Sciences, Warsaw University of Life Sciences, 02-787, Warsaw, Poland. ⁴Department of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, 3010, Australia. ⁵Department of Chemistry, Chonnam National University, Gwangju, 61186, Republic of Korea. ⁶Queensland Tropical Health Alliance, Smithfield, Queensland, 4878, Australia. *email: a.hofmann@griffith.edu.au

Library	Origin	Number of compounds	Number of hits ($ \Delta T_m > 1.5$ K)
Natural products	Local chemistry research groups	531	28
Pathogen Box	Medicines for Malaria Venture, Geneva, Switzerland	400	80
CSIRO synthetic library (representative subset)	CSIRO, Melbourne, Australia	2070	133
Open Scaffolds Library (representative subset)	Compounds Australia, Griffith University	2451	22
	Total	5452	263

Table 1. Compound libraries screened in the ligand binding assay.

trehalose-6-phosphate phosphatase^{19,20}, which is a conserved metabolic enzyme of many pathogens, absent from their mammalian hosts, that catalyses the formation of trehalose. This non-reducing disaccharide constitutes an essential metabolite in many micro-organisms but is neither required nor synthesised by vertebrates. Of the five known trehalose biosynthesis pathways, the so-called OtsAB pathway is the most common and employs trehalose-6-phosphate phosphatase (TPP; Enzyme Commission number 3.1.3.12) for the dephosphorylation of trehalose-6-phosphate (T6P), which is synthesised from uridine diphosphate-glucose and glucose-6-phosphate by trehalose-6-phosphate synthase²¹. The observation that TPP knockdown results in lethal phenotypes in the free-living nematode *Caenorhabditis elegans*²² and *Mycobacterium tuberculosis*²³, combined with the high conservation of this biosynthetic enzyme in pathogenic species¹⁹ has recently focused efforts of target-based drug discovery on pathogen TPPs (reviewed in²⁴).

Previous research efforts have targeted the synthesis of carbohydrate-based substrate mimics with first attempts exploring the usability of the sulphate analogue of T6P, trehalose-6-sulphate. While this analogue showed inhibition of TPPs from different nematode and bacterial organisms, the observed inhibition constants were in the range of 0.05–0.3 mM^{25,26}. Recent attempts aimed at phosphonic acid analogues of T6P yielded three compounds with IC₅₀ values in the high micromolar range (288–1959 μ M)²⁷. The trehalase inhibitor validamycin A, an antibiotic compound from *Streptomyces hygroscopicus* with topological similarity to trehalose²⁸, was reported to inhibit mycobacterial TPPs in the millimolar range (IC₅₀ values 12.6–15.0 mM)²⁷. Since carbohydrate chemistry is notoriously challenging and requires delicate protection and de-protection steps during the syntheses of the desired target molecules, an alternative synthetic strategy is to replace one of the two carbohydrate units of trehalose with aryl moieties. The best performing inhibitor from a recently published set of aryl-*D*-glucopyranoside-6-sulphate derivatives inhibited nematode and bacterial TPPs with inhibition constants in the range of 5–100 μ M²⁹.

In 2007, the Queensland Compound Library, now called Compounds Australia, was established as a national resource and dedicated compound management facility to support biomedical research efforts through the consolidation of small molecules into a repository that facilitates subsequent screening³⁰. The compound repository includes collections from academic researchers as well as commercially sourced compounds and augments a large variety of drug discovery efforts, including target-based drug discovery programs³¹.

Here, we used compound collections from local academic research groups, the public-private partnership Medicines for Malaria Venture as well as Compounds Australia to evaluate selected diverse compound groups for interactions with pathogen TPPs.

Results

Screening of compound libraries against *A. ceylanicum* TPP. Given the exquisite substrate specificity of TPPs^{32–35}, there is a strict requirement for the original and rather expensive substrate trehalose-6-phosphate in enzyme assays testing the activity and inhibition of these proteins. Therefore, we employed an economical two-tiered screening approach that consisted of a first-stage screening of compound libraries with a ligand binding assay based on thermal protein denaturation and a second-stage validation of hits in enzyme activity assays^{31,36}.

For the ligand binding assay, *A. ceylanicum* TPP was used as a target against which four different compound libraries were screened for potential effectors. The chosen libraries comprised purified or re-synthesised natural products from local chemistry groups, the Pathogen Box from Medicines for Malaria Venture (MMV), as well as representative subsets of the CSIRO synthetic library³⁷ and the Open Scaffold Collection³⁸ available from Compounds Australia at Griffith University (see Table 1). Using a minimum temperature difference of 1.5 K between experiments in the presence and absence of compound as cutoff criterion, 263 hits were identified of a total of 5452 compounds tested, which corresponds to an overall hit rate of 4.8%. All compounds were tested in triplicate, requiring 182 multi-well differential scanning fluorimetry experiments; the mean temperature at the inflection point of the *Accey*-TPP (negative control) unfolding curves was $46.2^\circ\text{C} \pm 0.2^\circ\text{C}$ using a confidence interval of 95%.

Of the hits obtained from the ligand binding assay, 222 compounds were tested as competitive inhibitors at a concentration of 25 μ M in an endpoint assay of phosphatase activity by *A. ceylanicum* TPP using T6P as the substrate; 41 compounds were not available at the time for further experiments. In this validation step, *N*-(phenylthio)phthalimide (1) of the CSIRO library displayed greater than 50% inhibition of *Accey*-TPP enzyme activity compared with the control experiment without inhibitors.

Evaluation of a phthalimide analogue series against pathogen TPPs. To obtain preliminary information about structure-activity relationships, seven analogues (2–8; Fig. 1A) were evaluated in addition

Figure 1. Evaluation of the enzyme inhibition properties of the hit compound and an analogue series. **(A)** Structures of the original hit *N*-(phenylthio)phthalimide (**1**) and a series of readily available analogues (**2–8**) investigated in this study. The structures were drawn by the authors using the software cDraw⁶⁰. **(B)** Results of inhibition experiments in the phosphatase enzyme assay of the TPPs from *A. ceylanicum* (light grey), *T. canis* (dark grey) and *H. contortus* (blue) using T6P as substrate and no or 25 μ M of compound. Only the original hit compound **1** displayed substantial reduction of the phosphatase activity. Bars indicate the mean relative activity of three independent experiments; error bars indicate the standard error. Statistical significance of the difference between **1–8** and the control experiment is indicated using asterisks.

to *N*-(phenylthio)phthalimide (**1**) for their inhibitory properties at a concentration of 25 μ M in the phosphatase endpoint assays for TPPs from each *A. ceylanicum*, *T. canis* and *H. contortus* (Fig. 1B). Compared with the uninhibited enzymes, **1** resulted in 82% inhibition of *Hcon*-TPP1 and complete annihilation of *Acey*-TPP and *Tcan*-TPP enzyme activity, respectively. However, neither phthalimide (**3**) nor any of the other six phthalimide analogues elicited any substantial inhibition of nematode TPP enzyme activity beyond 20%.

In addition to nematode TPPs, we evaluated the effects of **1** on TPPs from bacteria (*Mycobacterium tuberculosis*, *Stenotrophomonas maltophilia*, *Pseudomonas aeruginosa* and *Streptococcus pneumoniae*) available in our laboratories. Of the four distinct enzymes tested, only the extra-chromosomal TPP from *P. aeruginosa* was susceptible to inhibition by **1** (Fig. 2). The inhibitory effects of **1** on nematode TPPs (Fig. 3A) as well as *Paer*-ecTPP were quantified in dose-response experiments, with apparent inhibition constants in the range of 0.6–2.1 μ M (Table 2), assuming a competitive inhibition model.

Evaluation of redox sensitivity. Since the thioether linkage in **1** might allow involvement of this compound in redox reactions, the effect of different environmental redox states was evaluated. Therefore, phosphatase endpoint assays of *Acey*-TPP and *Tcan*-TPP were repeated in the presence and absence of 1 mM DL-1,4-dithiothreitol (DTT) in the reaction buffer as well as in the presence and absence of 25 μ M of **1**.

The results demonstrated that the presence of 1 mM DTT did not substantially affect the enzymatic activity of the two nematode enzymes which only showed a marginal increase of activity (*Acey*-TPP: +7%; *Tcan*-TPP: +1%; see Fig. 4). However, the inhibitory effect of **1** on the phosphatase activity of either enzyme was entirely suppressed under reducing conditions.

Evaluation of the inhibition mechanism. Based on the observed redox sensitivity of TPP inhibition by **1**, we reasoned that a probable inhibition mechanism might involve conjugation of the protein, and we hypothesised that cysteine side chains constitute the most likely conjugation sites. Previously, we derived a topological classification of mono-enzyme TPPs based on a survey of genomes and structure-based amino acid sequence alignments and classified the enzymes into three groups: nematodes, mycobacteria and bacteria¹⁹. Notably, all members of the nematode TPP group share a strictly conserved cysteine residue situated at the ‘back end’ of the substrate binding pocket at the interface between the cap and the core domain (see Supplementary Fig. S1; *Acey*-TPP: Cys209, *Tcan*-TPP: Cys215, *Bmal*-TPP: Cys222).

Using a molecular dynamics (MD) simulation of a solvated model of *B. malayi* TPP – currently the only nematode TPP with a known experimental three-dimensional structure – we investigated the binding of the substrate trehalose-6-phosphate in the active site. The binding pose obtained from the MD simulation was characterised by a parallel stacking interaction of the phosphorylated glucose unit with Tyr221 (distance ~4 Å; Supplementary Fig. S2) and the phospho group projecting towards the magnesium cofactor. The glucose moiety distal to the phospho group in trehalose-6-phosphate extended into a pocket ‘behind’ Tyr221, and was held in place by hydrogen bonds between the primary alcohol in the 4′-position on the substrate and backbone carbonyl groups of

Figure 2. Evaluation of *N*-(phenylthio)phthalimide as inhibitor of bacterial TPPs. *N*-(phenylthio)phthalimide (**1**) was tested at a concentration of 25 μM as competitive inhibitor of the phosphatase activity of the bacterial TPPs from *M. tuberculosis*, *S. maltophilia*, *P. aeruginosa* (extra-chromosomal TPP) and *S. pneumoniae*. Comparison of phosphatase activity in the absence (black) and presence of **1** (grey) revealed a significant reduction of enzymatic activity only for the enzyme from *P. aeruginosa*. Bars indicate the mean relative activity of three independent experiments; error bars indicate the standard error. Statistical significance of the difference between inhibition and control experiment is indicated using asterisks.

Figure 3. Comparison of dose-response data of *N*-(phenylthio)phthalimide in the phosphatase and nematode assays. **(A)** Dose-response data obtained for *N*-(phenylthio)phthalimide (**1**) in the phosphatase endpoint assay using the TPPs from *A. ceylanicum* (light grey), *T. canis* (dark grey) and *H. contortus* (blue). The enzymatic activity of either enzyme can be almost entirely suppressed by **1** at a concentration $>250 \mu\text{M}$ (*A. ceylanicum*), $>25 \mu\text{M}$ (*H. contortus*) and $>5 \mu\text{M}$ (*T. canis*), respectively. IC_{50} values are summarised in Table 2. **(B)** Dose-response data obtained for **1** (after 24 h exposure) in L3 larvae survival assays indicate half maximum lethal concentrations of $9.3 (\pm 1.4) \mu\text{M}$ for *T. cati* and $61 \mu\text{M}$ for *T. canis*. The two data points for *H. contortus* represent motility inhibition at compound concentrations of $25 \mu\text{M}$ and $100 \mu\text{M}$, respectively.

Enzyme	IC ₅₀ (μM)	app. K _i (μM)
Acey-TPP	2.8 ± 0.29	1.0
Tcan-TPP	0.89 ± 0.037	0.56
Hcon-TPP1	6.6 ± 0.36	5.8
Paer-ecTPP	2.1 ± 0.19	2.1

Table 2. Half maximal inhibitory concentrations and derived apparent inhibition constants of *N*-(phenylthio)phthalimide against selected TPPs.

Figure 4. The inhibitory effect of *N*-(phenylthio)phthalimide on the phosphatase activity of nematode TPPs is redox-dependent. *N*-(phenylthio)phthalimide (**1**) was tested at a concentration of 25 μM as competitive inhibitor of the phosphatase activity of the TPPs from *A. ceylanicum* (light grey) and *T. canis* (dark grey) in the absence and presence of 1 mM DTT. The inhibitory effect of **1** was entirely suppressed under reducing conditions. Bars indicate the mean relative activity of three independent experiments; error bars indicate the standard error. Statistical significance of the difference between inhibition and control experiments is indicated using asterisks.

Gly328 (cap domain) and Cys222. Intriguingly, this arrangement suggests that a suitably reactive group of an active site ligand might be able to form a covalent bond with the side chain of Cys222 since the 4'-hydroxyl-O was stably located at a distance of ~3.5 Å from the thiol-S of Cys222 (Supplementary Fig. S3).

In order to test whether this conserved cysteine residue was involved in the mechanism of inhibition of **1**, we generated a mutant *T. canis* TPP in which Cys215 was replaced with a serine. As evident in Fig. 5, the presence of compound **1** did not affect the enzymatic activity of the mutant protein *Tcan*-TPP-C215S, indicating that the binding of **1** to the side chain of cysteine 215 was a requirement for the inhibition of enzyme activity. The analysis of wild-type *Tcan*-TPP incubated with compound **1** by mass spectrometry confirmed that Cys215 and Cys415 were indeed conjugated with a thiophenyl moiety (Supplementary Fig. S4).

Effects of *N*-(phenylthio)phthalimide on nematodes. To evaluate whether *N*-(phenylthio)phthalimide (**1**) also possessed anthelmintic effects, the compound was tested in nematode survival³⁹, migration (*T. canis*, *T. cati*)⁴⁰ and motility assays (*Haemonchus contortus*)⁴¹. Whereas the motility of exsheathed *H. contortus* larvae (xL3) was only weakly impaired at a compound concentrations of 25 μM and 100 μM (Fig. 3B), the exposure of *Toxocara* larvae to 100 μM of compound **1** resulted in >80% lethality after 24 h (*T. canis*) and 3 h (*T. cati*), respectively (see Supplementary Fig. S5). The analysis of dose-response data acquired after 24 h exposure to varying concentrations of **1** resulted in half maximum lethal concentrations of 9.3 μM for *T. cati* and 61 μM for *T. canis*, respectively (Fig. 3B).

Figure 5. The inhibitory effect of *N*-(phenylthio)phthalimide on the phosphatase activity of *T. canis* TPP requires cysteine 215. *N*-(phenylthio)phthalimide (**1**) was tested at a concentration of 25 μ M as competitive inhibitor of the phosphatase activity of wild-type (black) and the C215S mutant (grey) TPP from *T. canis* in the absence and presence of 1 mM DTT. The enzymatic activity of the mutant was not affected by **1**. Bars indicate the mean relative activity of three independent experiments; error bars indicate the standard error. Statistical significance of the difference between inhibition and control experiments is indicated using asterisks.

Discussion

Identification of *N*-(phenylthio)phthalimide as a novel inhibitor of nematode TPP enzyme activity. Owing to the exquisite substrate selectivity of trehalose-6-phosphate phosphatases and the rather costly resourcing of its substrate trehalose-6-phosphate, we designed a two-tiered approach for the high-throughput screening of compounds targeting these enzymes. The screening approach consisted of a ligand binding assay and a subsequent enzyme assay as the validation step for prioritised compounds from the ligand binding assay. Using this approach, a natural products library, the MMV Pathogen Box and representative subsets of two compound libraries available through Compounds Australia were mined for potential inhibitors of *Accey*-TPP.

These efforts resulted in the identification of **1** as a potent inhibitor of the phosphatase activity of TPP from *A. ceylanicum*. Subsequent evaluation of inhibition activity with respect to *T. canis* and *H. contortus* TPPs as well as a panel of four bacterial TPPs revealed that **1** preferentially inhibits the nematode enzymes with apparent inhibition constants of 0.6 μ M, 1 μ M and 6 μ M against *Tcan*-TPP, *Accey*-TPP and *Hcon*-TPP1, respectively. Being one order of magnitude lower than previously reported compounds, these values make **1** the most potent nematode TPP inhibitor at present.

Mechanism of enzyme inhibition. *N*-(phenylthio)phthalimide (**1**) is a close analogue of the fungicide folpet (*N*-(trichloromethylthio)phthalimide) and its partially saturated derivatives captan (*N*-(trichloromethylthio)tetrahydrophthalimide) and captafol (difolatan; *N*-(tetrachloroethylthio)tetrahydrophthalimide). Previously, it has been shown that these chloroalkyl sulfenamides can be conjugated to free thiols, thereby oxidising the thiol to its disulfide and liberating the phthalimide moiety⁴².

Thus, it is plausible that the thiophenyl group of **1** may be conjugated to a cysteine side chain of the nematode TPPs studied to afford a phenylcysteine disulfide modification of the proteins, presumably via an S_N2 attack of the thiolate on the sulfenamide⁴³. Mass spectrometric investigation of *Tcan*-TPP that had been incubated with **1** confirmed thiophenyl conjugation of the cysteine residues at positions 215 and 415.

Reducing conditions, established by the presence of 1 mM DTT, suppressed the inhibitory effect of **1** on the activity of *Accey*-TPP and *Tcan*-TPP, in agreement with earlier observations made with folpet where modification of glyceraldehyde-3-phosphate dehydrogenase by the fungicide was almost entirely prevented in the presence of either 1 mM DTT or reduced glutathione⁴⁴. The suppressed modification of cysteine side chains in a reducing environment might be due to rapid cleavage of the disulfide reaction product of the conjugation reaction or, indeed, cleavage of the sulfenamide and thus loss of the reactant.

The amino acid sequences of nematode TPPs contain several cysteine residues (*A. ceylanicum*: seven, *T. canis*: eight) of which four are strictly conserved throughout the species examined. Importantly, in our previous

studies¹⁹, we noticed that one of these conserved cysteine residues is located in the interface between the cap and core domains of the haloacid dehydrogenase (HAD) fold (Pfam identifier: PF08282), backing on to the substrate binding site. Computational modelling of the substrate-bound TPP from *B. malayi* indicated that the side chain of this conserved cysteine residue maintained a distance of ~3.5 Å to the non-phosphorylated glucose moiety of T6P and was thus in close proximity to the substrate in the active site (Supplementary Figs S2 and S3). Therefore, we reasoned that, given the similarity between T6P and *N*-(phenylthio)phthalimide in terms of their spatial extents and topologies, the latter might be able to populate the substrate binding site and then react with the conserved cysteine residue under non-reducing redox conditions. The absence of any inhibitory activity by **1** when testing the C215S mutant of *T. canis* TPP, fully supports this hypothesis.

Furthermore, the absence of inhibitory effects of **1** on the activity of most bacterial TPPs is in accordance with the proposed mechanism, as bacterial TPPs lack the conserved residue in the core/cap interface. The only exception within the panel of bacterial TPPs tested here is the enzyme from *Pseudomonas aeruginosa* which was susceptible to inhibition by **1** (Fig. 2) with an apparent K_i of 2.1 µM (Table 2). The reason for this susceptibility is not entirely clear, but we speculate that the conjugation of one or both cysteine residues specific to *P. aeruginosa* (Cys85, Cys231) might lead to conformational alterations that restrict access to the substrate binding site. In particular, it seems likely that modification of the side chain of Cys85 causes a rearrangement of the residues lining the rather narrow access to the active site³⁵.

Anthelmintic properties of *N*-(phenylthio)phthalimide. In order to assess whether findings from the target-based approach can be translated into therapeutic applications, whole organism assays were conducted using two *Toxocara* species (Ascarididae) and *H. contortus* (Trichostrongylidae). Whereas *Toxocara* larvae were susceptible to *N*-(phenylthio)phthalimide with half maximum lethal concentrations in the micro-molar range, no significant effects were observed in motility assays of *H. contortus* larvae despite the inhibitory activity of this compound on the enzyme activity of *Hcon*-TPP1. At present, the reason for this difference in bioactivity remains unclear. It is possible that genus-specific features might have to be considered and/or a different life cycle stage of *Haemonchus* would need to be evaluated (e.g., by employing an egg hatch assay).

Conclusions

Here, we outlined the application of a 'systems' approach to target-based drug discovery. The characterisation and appraisal of a target protein from a range of different organisms capitalises on the advances of 'omics disciplines over the past decade and the resultant growing resources in the form of genome and transcriptome datasets. Following selection of trehalose-6-phosphate phosphatase (TPP) as a target of interest and structural appraisal of TPPs from many different pathogenic organisms, these enzymes could be classified into groups¹⁹ and representatives of each group selected for experimental investigation.

TPPs hold major promise as novel targets of infectious diseases since these enzymes are essential for nematode and mycobacterial pathogens, but are absent from mammalian hosts. Drug discovery strategies for TPPs used thus far have concentrated on the design of substrate mimics, which is challenging due to the fragile behaviour of carbohydrates in chemical syntheses. The clear objective was thus to discover TPP inhibitors with novel chemotypes that provide new avenues for chemical synthetic approaches. Structure-based amino acid sequence analysis of TPPs across different phyla suggested the hypothesis of covalent inhibition of nematode TPPs targeting a nematode-specific cysteine residue in the vicinity of the active site. This hypothesis was tested utilising compound libraries to screen a recombinant nematode TPP and identify novel ligands. The ability of those ligands to inhibit the enzyme activity of TPPs from nematode and bacterial organisms was then evaluated in enzyme assays, revealing that *N*-(phenylthio)phthalimide was a highly effective and specific inhibitor for nematode TPPs. This compound conjugates a strictly conserved cysteine residue in the active site of nematode TPPs and therefore acts as a suicide inhibitor. Whole organism assays with nematode larvae show that *N*-(phenylthio)phthalimide also possesses promising anthelmintic properties against two tested ascaroid species.

These results suggest that TPPs can be worthwhile targets for novel anthelmintics, albeit we can not exclude the possibility that *N*-(phenylthio)phthalimide might also affect other targets in nematodes. Although the particular redox activity of this compound and close analogues may be a hindrance for commercial development, it presents a much needed probe for future studies on TPPs and proof-of-concept for developing covalent, non-substrate-like inhibitors of nematode TPPs.

Materials and Methods

Protein expression and purification. The TPPs investigated in this study included the enzymes from the nematodes *A. ceylanicum*, *T. canis* and *H. contortus*; the bacteria *M. tuberculosis*, *Stenotrophomonas maltophilia* and *Streptococcus pneumoniae*; and the extrachromosomal TPP from *P. aeruginosa*^{35,45}. All proteins were expressed and purified as over-expressed recombinant proteins according to our previously published protocol⁴⁵. For *H. contortus*, an expression construct in vector p11 (Bioscience Resource Project, Arizona State University, Tempe, AZ, USA) was generated using the codon-optimised synthetic cDNA (GenScript, Piscataway Township, NJ, USA) of *Hcon*-TPP transcript¹⁹. In brief, the N-terminally hexa-His fusion constructs of all proteins in vector p11 were transformed into *Escherichia coli* BL21-AI cells and 8 litre production cultures in LB+ medium⁴⁶ were seeded from 1 litre of overnight liquid culture. The production culture was grown at 37 °C for 4 h and induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 0.2% arabinose after lowering the temperature to 20 °C. Incubation continued for 40 h, after which cells were harvested, subjected to multiple freeze-thaw cycles, a 5 min sonication and clarification of the cytosolic fraction by high-speed centrifugation. The recombinant proteins were purified by ion exchange and immobilised metal ion affinity chromatography, followed by the removal of the N-terminal hexa-His-fusion peptide by proteolysis with in-house produced tobacco etch virus (TEV) protease. All stages of protein purification were monitored by SDS-PAGE analysis to verify the expected molecular masses for the target proteins.

Screening of compounds by ligand binding assay. Compound libraries were obtained from local chemistry groups or purchased from Compounds Australia. The libraries were screened in a ligand binding assay against *Acey*-TPP that evaluated the thermal protein denaturation monitored by fluorescence emission of an amphiphilic dye in reaction mixes with and without small molecule compounds (differential scanning fluorimetry; DSF). The optimal ratio of protein and fluorescence dye for a two-state unfolding curve was optimised by testing a 7×4 matrix of conditions varying the protein concentration from 0.5 to $32 \mu\text{M}$, and SYPRO Orange (Invitrogen; Life Technologies, Mulgrave, VIC, Australia) concentration between $5\times$ and $20\times$ in a sample volume of $20 \mu\text{L}$ with a buffer composed of 100 mM NaCl and 20 mM HEPES (pH 7.5)⁴⁶. For *Acey*-TPP, the best conditions were determined to contain $0.5 \mu\text{M}$ protein and $5\times$ SYPRO Orange.

DSF experiments were carried out in 96-well plates using a Roche LightCycler 480 (Roche, Basel, Switzerland). Three technical replicates were tested for each ligand, along with three replicates of a protein-buffer and a protein-DMSO mixture per 96-well plate. Each reaction mixture comprised the optimised protein:dye ratio in a total volume of $20 \mu\text{L}$. Ligands were added from their stock solutions in DMSO at a final concentration of $2.5\text{--}5 \mu\text{M}$, with a final DMSO concentration of 5%. Experiments were analysed using the software DMAN⁴⁷, and ΔT_m values were calculated as the difference between ligand and DMSO control experiments.

Phthalimide analogue series. Compounds **1** and **2** were obtained from Combi-Blocks (San Diego, USA) and used as received. For revalidation purposes, compound **1** was also sourced from abcr (Karlsruhe, Germany). Compound **3** was obtained from Sigma-Aldrich (Castle Hill, NSW, Australia). Compounds **4–8** were obtained from the CSIRO compound collection.

Enzyme end-point assays. Trehalose-6-phosphate was synthesised in-house as published previously¹⁹ and also purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Phosphatase end-point assays were carried out following a previously established protocol³⁵. Briefly, the phosphatase activity of *Acey*-TPP and *Tcan*-TPP was assessed using $500 \mu\text{M}$ trehalose-6-phosphate and $10 \mu\text{M}$ enzyme to be tested. Reactions were carried out in a volume of $50 \mu\text{L}$ in assay buffer (100 mM NaCl , 20 mM TRIS , pH 7.5). Individual compounds were added to the reaction mixtures at a final concentration of $25 \mu\text{M}$, followed by incubation for 5 min before reactions were initiated by the addition of substrate (final DMSO concentration of 4%).

Reactions were allowed to proceed for 5 min before quenching with $100 \mu\text{L}$ of BIOMOL® Green reagent (Enzo Life Sciences, New York, NY, USA). Absorbance at 620 nm was determined using a BioTek® Synergy 2 plate reader (BioTek, Winooski, VT, USA) after an incubation period of 15 min for colour development. All reactions were set up in triplicate in 96-well plates (Corning, Sigma-Aldrich, NSW, Australia) at 25°C and control experiments in the absence of enzyme were used to correct for background absorbance.

Raw data were exported as spreadsheets from the plate reader and assembled for statistical analysis with R⁴⁸ using the software jBar⁴⁹ for calculation of means and standard errors, background correction, normalisation and significance evaluation by a two-sided *t*-test.

To determine IC_{50} values, end-point assays were performed in the presence of increasing concentrations of compound (2.5 nM to $250 \mu\text{M}$). Compounds were prepared in stocks of increasing concentration such that only $2 \mu\text{L}$ was added to reaction wells, thus keeping the DMSO concentration consistent at 4%. Enzyme in the absence of compound (with DMSO only) was run as a control and after correction for background absorbance, all test wells were scaled relative to the enzyme-only control. IC_{50} values were determined through fitting using either the software application SDAR⁵⁰ or DRfit⁵¹.

Mass spectrometry. Mass spectrometric analyses were carried out at the Australian Proteome Analysis Facility (APAF) and the following description of methodologies were obtained from the APAF General Report form (A-011 version 3).

To determine possible modification of *Tcan*-TPP by *N*-(phenylthio)phthalimide, the protein was diluted to a final concentration of 1 mg mL^{-1} into a buffer containing $25 \mu\text{M}$ of **1**, 100 mM NaCl , 0.2 mM MgCl_2 and 20 mM TRIS (pH 7.5). For in-solution digestion, $20 \mu\text{L}$ of the protein solution were mixed with $5 \mu\text{L}$ of 100 mM triethylammonium bicarbonate (TEAB) and $1 \mu\text{g}$ trypsin was added. After incubation at 37°C for 5.5 h, $2.5 \mu\text{L}$ of the digested sample were diluted into $7.5 \mu\text{L}$ of TEAB buffer.

The final sample was subjected to 1D-nano-LC ESI MS/MS analysis using a model 6600 Sciex mass spectrometer and an Eksigent nanoLC-Ultra HPLC system with HALO C18 analytical ($160 \text{ \AA}$, $2.7 \mu\text{m}$, $200 \mu\text{m} \times 20 \text{ cm}$) and trap ($160 \text{ \AA}$, $2.7 \mu\text{m}$, $150 \mu\text{m} \times 3.5 \text{ cm}$) columns. The loading buffer contained 2% acetonitrile, 97.9% water and 0.1% formic acid; mobile phases A and B consisted of 99.9% water and 0.1% formic acid, and 99.9% acetonitrile and 0.1% formic acid, respectively. The sample ($10 \mu\text{L}$) was injected onto a reverse-phase trap for pre-concentration and desalted with loading buffer, at $4 \mu\text{L min}^{-1}$ for 10 min. The peptide trap was then switched into line with the analytical column. Peptides were eluted from the column using a linear solvent gradient from mobile phase A: mobile phase B (98:2) to mobile phase A: mobile phase B (76:24) over 55 min. The reverse phase nano-LC eluent was subjected to positive ion nanoflow electrospray analysis in an information-dependent acquisition mode. A TOF-MS survey scan was acquired (m/z 350–1500, 0.25 s) with the 20 most intense multiply charged ions (2^+ – 5^+ ; exceeding 200 counts per second) in the survey scan sequentially subjected to MS/MS analysis. MS/MS spectra were accumulated for 100 ms in the mass range m/z 100–1800 with rolling collision energy. Dynamic exclusion was set to 30 s.

The sequence of *Tcan*-TPP was added to a database of *E. coli* proteins (23,043 sequences) and the LC-MS/MS data were searched against this database using ProteinPilot v5.0 (SCIEX) in Thorough mode. A custom modification of thiophenyl ($\text{C}_6\text{H}_5\text{S}$, monoisotopic mass: 109.011196 Da) on cysteine was added to the list of modifications.

Animal ethics. For work with *T. canis* and *T. cati* (Warsaw University of Life Sciences, Poland), no ethics approval was required as no animals were involved in clinical-diagnostic procedures other than requested for their health and with owner permission.

H. contortus (Haecon-5 strain) was maintained in experimental sheep (male; 6–8 weeks of age), maintained helminth-free, and housed at the University of Melbourne, as described previously^{41,52}. The use of sheep was approved by the Institutional Animal Care and Use Committee of the University of Melbourne (permit no. 1413429). All animal experiments were performed in accordance with the Australian National Health Medical Research Council (Australian code of practice for the care and use of animals for scientific purposes, 7th Edition, 2004, ISBN: 1864962658).

Toxocara larvae assays. For the survival assay, an average number of 150 L3 larvae were incubated in 24-well culture plates with serial dilutions of **1** (100 μM –6.25 μM) in Minimal Essential Medium for 24 h at 37 °C, 5% CO_2 . Control larvae were maintained in 0.4% DMSO in Minimal Essential Medium. The survival of L3s exposed to the compound was assessed at several time points after the start of the incubation using a light microscope (at 40 $\times$ magnification). Larvae were considered alive if they had a characteristic coiled appearance and were motile; they were considered dead if they appeared straight and immobile even after extended observation³⁹.

To assess migration, 150 L3 larvae were incubated in different concentrations of **1** (6.25 μM –100 μM). After 24 h of incubation (37 °C, 5% CO_2), an equivalent volume of 1.5% agar was added to each well⁴⁰. The agar was allowed to set prior to the addition of 0.3 ml of phosphate-buffered saline to each well and the plates were again incubated for 24 h at 37 °C, 5% CO_2 . The number of larvae that migrated to the top of the well was counted using a light microscope (at 40 $\times$ magnification).

H. contortus larvae assays. The effects of compound **1** were assessed in a motility assay using exsheathed third-stage larvae (xL3s) of *H. contortus* in 96-well microculture plates (Corning 3635; Life Sciences, USA) and the control compounds moxidectin and monepantel, following the published protocol⁵³. In brief, **1** was diluted to the final concentration of 100 μM using Luria Bertani medium (LB) supplemented with 100 IU/mL of penicillin, 100 $\mu\text{g mL}^{-1}$ of streptomycin and 2.5 $\mu\text{g mL}^{-1}$ of amphotericin (LB*), and then dispensed in triplicate into wells of a 96-well microculture plate using a multichannel pipette. Additionally, the negative controls (LB*, LB* + 0.5% solvent; six wells each), and positive controls (20 μM monepantel; Zolvix, Novartis Animal Health, Switzerland and 20 μM moxidectin; Cydectin, Virbac, France; triplicate wells) and xL3s (~300 per well) were dispensed into wells of the plate using an automated multichannel pipette. Following incubation at 38 °C and 10% CO_2 for 72 h, a video recording of 5 s duration was taken of each well using a grayscale camera (Rolera Bolt, QImaging, Canada) and a motorized X-Y axis stage (BioPoint2, Ludl Electronic Products, USA). Videos were processed to calculate a motility index (MI) using an algorithm described previously⁴¹.

Modelling of substrate-bound *B. malayi* TPP. As the deposited crystal structures of *Bmal*-TPP (PDB accession codes 4ofz, 5e0o) lacked several residues due to absence of electron density, we generated a model that included residues 63–491 based on the structure deposited as 4ofz. The resultant model was solvated and subjected to a molecular dynamics (MD) simulation of 20 ns to reduce possible bias.

Using the completed model of *Bmal*-TPP, trehalose-6-phosphate was placed in the vicinity of the presumed binding pocket, but without direct interactions of ligand groups with protein amino acid residues. The binding of the substrate was then investigated by an MD simulation of the solvated system for a period of 20 ns. The results showed that the system attained an apparent equilibrium state after ~3 ns (Supplementary Fig. S3). After ~7.5 ns, the ligand had manoeuvred itself into a binding pose that remained stable for the remainder of the simulation period. Both MD simulations (*Bmal*-TPP in water, *Bmal*-TPP:T6P in water) followed a protocol reported earlier³⁵ and were carried out with Gromacs 4.6.5⁵⁴ using the G43a1 force field and the spc water model; the topology for T6P was calculated using the PRODRG2 server⁵⁵. The ligand was manually placed in the binding site with the phospho group projecting away from the magnesium cofactor. Sodium and chloride ions were added by replacing solvent molecules at sites of high electrostatic potential to ensure a charge-neutral cell and at a concentration of 100 mM. For all simulations, periodic boundary conditions were applied in all three dimensions. Following an energy minimisation step, a position-restrained dynamics simulation of 20 ps with a time step of 2 fs was performed to equilibrate the solvated protein complex and gradually equilibrate the system at 300 K and 1 bar. In order to model long-range interactions, the particle mesh Ewald method⁵⁶ was employed with a grid spacing of 1.2 Å. Short-range electrostatic interactions were calculated with a 10 Å cutoff, and for van der Waals interactions a cutoff of 14 Å was used. Temperature and pressure in the simulation cell were controlled with the V-rescale thermostat⁵⁷ and the Parrinello-Rahman barostat⁵⁸, respectively. All bonds were constrained using the LINCS algorithm⁵⁹. The final MD simulation was performed for 20 ns with a time step of 1 fs. Simulations were performed on a custom-built server with an Intel Xeon E5-1650 Six Core (3.5 GHz) and 32 GB RAM. Analyses were performed with Gromacs tools and plots were generated with Grace (<http://plasma-gate.weizmann.ac.il/Grace/>).

Received: 15 July 2019; Accepted: 28 August 2019;

Published online: 07 November 2019

References

1. Matos, M., Alho, A. M., Owen, S. P., Nunes, T. & Madeira de Carvalho, L. Parasite control practices and public perception of parasitic diseases: A survey of dog and cat owners. *Prev. Vet. Med.* **122**, 174–180 (2015).
2. World Health Organisation. Accelerating work to overcome the global impact of neglected tropical diseases, http://apps.who.int/iris/bitstream/10665/70809/1/WHO_HTM_NTD_2012.1_eng.pdf, Available at, http://apps.who.int/iris/bitstream/10665/70809/1/WHO_HTM_NTD_2012.1_eng.pdf, (Accessed: 11th November 2016) (2012).

3. Gasser, R. B., Bott, N. J., Chilton, N. B., Hunt, P. & Beveridge, I. Toward practical, DNA-based diagnostic methods for parasitic nematodes of livestock — Bionomic and biotechnological implications. *Biotechnol. Adv.* **26**, 325–334 (2008).
4. Lane, J., Jubb, T., Shephard, R., Webb-Ware, J. & Fordyce, G. *MLA final report: Priority list of endemic diseases for the red meat industries*. (MLA, 2015).
5. James, C. E., Hudson, A. L. & Davey, M. W. Drug resistance mechanisms in helminths: is it survival of the fittest? *Trends Parasitol.* **25**, 328–335 (2009).
6. Wolstenholme, A. J. & Kaplan, R. M. Resistance to macrocyclic lactones. *Curr. Pharm. Biotechnol.* **13**, 873–887 (2012).
7. Lindgren, E., Andersson, Y., Suk, J. E., Sudre, B. & Semenza, J. C. Monitoring EU emerging infectious disease risk due to climate change. *Science* **336**, 418–419 (2012).
8. Kares, W. B. *et al.* Ecology of zoonoses: natural and unnatural histories. *The Lancet* **380**, 1936–1945 (2012).
9. Inpankaew, T. *et al.* High prevalence of *Ancylostoma ceylanicum* hookworm infections in humans, Cambodia, 2012. *Emerg. Infect. Dis.* **20**, 976–982 (2014).
10. Smout, F. A. *et al.* The hookworm *Ancylostoma ceylanicum*: An emerging public health risk in Australian tropical rainforests and Indigenous communities. *One Health* **3**, 66–69 (2017).
11. Hotez, P. J. & Wilkins, P. P. Toxocariasis: America's most common neglected infection of poverty and a helminthiasis of global importance? *PLoS Negl. Trop. Dis.* **3**, e400 (2009).
12. Kleine, A., Springer, A. & Strube, C. Seasonal variation in the prevalence of *Toxocara* eggs on children's playgrounds in the city of Hanover, Germany. *Parasit. Vectors* **10**, 248 (2017).
13. Hsu, Y.-C. & Lin, J.-T. Intestinal infestation with *Ancylostoma ceylanicum*. *N. Engl. J. Med.* **366**, e20 (2012).
14. Poppert, S. *et al.* Diffuse unilateral subacute neuroretinitis caused by *Ancylostoma* hookworm. *Emerg. Infect. Dis.* **23**, 343–344 (2017).
15. Ma, G. *et al.* Human toxocariasis. *Lancet Infect. Dis.* **18**, e14–24 (2018).
16. Roeder, F., Jex, A. R. & Gasser, R. B. Impact of gastrointestinal parasitic nematodes of sheep, and the role of advanced molecular tools for exploring epidemiology and drug resistance - an Australian perspective. *Parasit. Vectors* **6**, 153 (2013).
17. Taylor, C. M. *et al.* Discovery of anthelmintic drug targets and drugs using chokepoints in nematode metabolic pathways. *PLOS Pathog.* **9**, e1003505 (2013).
18. Reddy, G. K., Rao, K. N. & Prasad, P. R. Identification of drug and vaccine targets in *Clostridium botulinum*-A by the approach *in-silico* subtractive genomics. *Int. J. Pharm. Stud. Res.* **2**, 48–54 (2011).
19. Cross, M. *et al.* Probing function and structure of trehalose-6-phosphate phosphatases from pathogenic organisms suggests distinct molecular groupings. *FASEB J.* **31**, 920–926 (2017).
20. Thammahong, A., Puttikamonkul, S., Perfect, J. R., Brennan, R. G. & Cramer, R. A. Central role of the trehalose biosynthesis pathway in the pathogenesis of human fungal infections: Opportunities and challenges for therapeutic development. *Microbiol. Mol. Biol. Rev.* **81**, e00053–16 (2017).
21. Avonce, N., Mendoza-Vargas, A., Moretti, E. & Iturriaga, G. Insights on the evolution of trehalose biosynthesis. *BMC Evol. Biol.* **6**, 109 (2006).
22. Kormish, J. D. & McGhee, J. D. The *C. elegans* lethal gut-obstructed gob-1 gene is trehalose-6-phosphate phosphatase. *Dev. Biol.* **287**, 35–47 (2005).
23. Korte, J. *et al.* Trehalose-6-phosphate-mediated toxicity determines essentiality of OtsB2 in *Mycobacterium tuberculosis* *in vitro* and in mice. *PLOS Pathog.* **12**, e1006043 (2016).
24. Cross, M. *et al.* Trehalose-6-phosphate phosphatase as a broad-spectrum therapeutic target against eukaryotic and prokaryotic pathogens. *Emerg. Top. Life Sci.* **1**, 675–683 (2017).
25. Farelli, J. D. *et al.* Structure of the trehalose-6-phosphate phosphatase from *Brugia malayi* reveals key design principles for anthelmintic drugs. *PLOS Pathog.* **10**, e1004245 (2014).
26. Liu, C., Dunaway-Mariano, D. & Mariano, P. S. Rational design of first generation inhibitors for trehalose 6-phosphate phosphatases. *Tetrahedron* **73**, 1324–1330 (2017).
27. Kapil, S., Petit, C., Drago, V. N., Ronning, D. R. & Sucheck, S. J. Synthesis and *in vitro* characterization of trehalose-based inhibitors of mycobacterial trehalose 6-phosphate phosphatases. *ChemBioChem*, **20**, 260–269 (2019).
28. Li, H. *et al.* Enhanced production of trehalose in *Escherichia coli* by homologous expression of otsBA in the presence of the trehalase inhibitor, validamycin A, at high osmolarity. *J. Biosci. Bioeng.* **113**, 224–232 (2012).
29. Liu, C., Dunaway-Mariano, D. & Mariano, P. S. Rational design of reversible inhibitors for trehalose 6-phosphate phosphatases. *Eur. J. Med. Chem.* **128**, 274–286 (2017).
30. Camp, D. Establishment of an open access compound management facility in Australia to stimulate applied basic and translational biomedical research. *Drug Discov. World* **8**, 61–66 (2007).
31. Hofmann, A., Wang, C. K., Osman, A. & Camp, D. Merging Structural Biology with Chemical Biology: Structural Chemistry at Eskitis. *Struct. Chem.* **21**, 1117–1129 (2010).
32. Klutts, S. Purification, cloning, expression, and properties of mycobacterial trehalose-phosphate phosphatase. *J. Biol. Chem.* **278**, 2093–2100 (2003).
33. Kushwaha, S., Singh, P. K., Rana, A. K. & Misra-Bhattacharya, S. Cloning, expression, purification and kinetics of trehalose-6-phosphate phosphatase of filarial parasite *Brugia malayi*. *Acta Trop.* **119**, 151–159 (2011).
34. Miao, Y. *et al.* Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis. *Proc. Natl. Acad. Sci.* **113**, 7148–7153 (2016).
35. Cross, M. *et al.* Trehalose 6-phosphate phosphatases of *Pseudomonas aeruginosa*. *FASEB J.* **32**, 5470–5482 (2018).
36. von Gnielinski, N. *et al.* Non-classical β -carbonic anhydrase inhibitors-towards novel anti-mycobacterials. *Med Chem Commun* **5**, 1563–1566 (2014).
37. Francis, C. L. *et al.* Construction of the CSIRO fragment library. *Aust. J. Chem.* **66**, 1473–1482 (2013).
38. Preston, S. *et al.* Screening of the 'Open Scaffolds' collection from Compounds Australia identifies a new chemical entity with anthelmintic activities against different developmental stages of the barber's pole worm and other parasitic nematodes. *Int. J. Parasitol. Drugs Drug Resist.* **7**, 286–294 (2017).
39. Williams, A. R. *et al.* Anthelmintic activity of *trans*-cinnamaldehyde and A- and B-type proanthocyanidins derived from cinnamon (*Cinnamomum verum*). *Sci. Rep.* **5**, 14791 (2015).
40. Zhao, J. *et al.* An *in vitro* larval migration assay for assessing anthelmintic activity of different drug classes against *Ascaris suum*. *Vet. Parasitol.* **238**, 43–48 (2017).
41. Preston, S. *et al.* Low cost whole-organism screening of compounds for anthelmintic activity. *Int. J. Parasitol.* **45**, 333–343 (2015).
42. Siegel, M. R. Reactions of certain trichloromethyl sulfonyl fungicides with low molecular weight thiols. *In vitro* studies with glutathione. *J. Agric. Food Chem.* **18**, 819–822 (1970).
43. Nti-Addae, K. W. & Stella, V. J. *In vitro* conversion of model sulfenamide prodrugs in the presence of small molecule thiols. *J. Pharm. Sci.* **100**, 1001–1008 (2011).
44. Siegel, M. R. Reactions of the fungicide folpet (N-(trichloromethylthio)phthalimide) with a thiol protein. *Pestic. Biochem. Physiol.* **1**, 225–233 (1971).
45. Cross, M. *et al.* Enzyme characteristics of pathogen-specific trehalose-6-phosphate phosphatases. *Sci. Rep.* **7**, 2015 (2017).
46. Hofmann, A. *Methods in Structural Biochemistry*. (Structural Chemistry Program, Griffith University, 2018).

47. Wang, C. K., Weeratunga, S. K., Pacheco, C. M. & Hofmann, A. DMAN: a Java tool for analysis of multi-well differential scanning fluorimetry experiments. *Bioinformatics* **28**, 439–440 (2012).
48. R Core Team. *R: A language and environment for statistical computing*. (R Foundation for Statistical Computing, 2016).
49. Hofmann, A. *et al.* A convenient tool for bivariate data analysis and bar graph plotting with R. *Biochem. Mol. Biol. Educ.* **47**, 207–210 (2019).
50. Weeratunga, S., Hu, N.-J., Simon, A. & Hofmann, A. SDAR: a practical tool for graphical analysis of two-dimensional data. *BMC Bioinformatics* **13**, 201 (2012).
51. Hofmann, A. *et al.* DRfit: a Java tool for the analysis of discrete data from multi-well plate assays. *BMC Bioinformatics* **20**, 262 (2019).
52. Schwarz, E. M. *et al.* The genome and developmental transcriptome of the stronglyid nematode *Haemonchus contortus*. *Genome Biol.* **14**, R89 (2013).
53. Preston, S. *et al.* Practical and low cost whole-organism motility assay: A step-by-step protocol. *Mol. Cell. Probes* **30**, 13–17 (2016).
54. van der Spoel, D. *et al.* GROMACS: Fast, flexible and free. *J Comp Chem* **26**, 1701–1718 (2005).
55. Schüttelkopf, A. W. & van Aalten, D. M. F. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 1355–1363 (2004).
56. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. *J. Chem. Phys.* **98**, 10089–10092 (1993).
57. Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. *J. Chem. Phys.* **126**, 014101 (2007).
58. Parrinello, M. & Rahman, A. Polymorphic transitions in single crystals: A new molecular dynamics method. *J. Appl. Phys.* **52**, 7182–7190 (1981).
59. Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations. *J. Comput. Chem.* **18**, 1463–1472 (1997).
60. Hofmann, A., Coster, M. J. & Taylor, P. Disseminating a free, practical Java tool to interactively generate and edit 2D chemical structures. *J. Chem. Educ.* **96**, 1262–1267 (2019).

Acknowledgements

MC was supported by an Equity Trustees PhD Scholarship as well as an Australian Government Research Training Program Scholarship. JHS was recipient of a DAAD RISE and SB of a DAAD PROMOS scholarship. Research in the investigators' laboratories is funded by the Australian Research Council (AH and RBG) and the Rebecca L. Cooper Medical Research Foundation (AH). Aspects of this research have been facilitated by access to the Australian Proteome Analysis Facility supported under the Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS).

Author contributions

Conceptualisation: A.H., R.B.G., J.S.K. and J.H.R.; Investigation: M.C., S.B., H.M.P.D.H., E.D., J.H.S. and A.H.; Resources: M.Y., S.A.L. and J.H.R.; Analyses: S.B., M.C., S.A.L., R.B.G. and A.H.; Writing – Original Draft: M.C. and A.H.; Supervision: A.H. and R.B.G.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-019-52593-9>.

Correspondence and requests for materials should be addressed to A.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019